Ikarovec

Developer of novel gene therapies for major ophthalmic indications.

Norwich, UK—Founded 2019

£3.0MTotal raised

Ikarovec is developing novel and differentiated gene therapies for major ophthalmic indications. The company builds on intellectual property spun out from Quethera.

Founders

Peter Widdowson

Chief Scientific Officer

Investors

Grant15 June 2020
£459K
Innovate UK
Seed5 February 2020
£2.5M
UK Innovation & Science Seed FundLead
LifeArc
Parkwalk

Funding history

Grant15 June 2020

£459K

Ikarovec secures £459k grant funding from Innovate UK to accelerate gene therapy development.

The grant from Innovate UK is matched by recent seed backing from LifeArc, Parkwalk and UKI2S.

Seed5 February 2020

£2.5M

Ikarovec secures £2.5m seed funding from UK Innovation & Science Seed Fund, LifeArc and Parkwalk to advance gene therapy pipeline.

The funding round was led by UK Innovation & Science Seed Fund with participation from LifeArc and Parkwalk.